A Randomized, Placebo Controlled, Subject and Investigator Blinded, first-in- Human, Single Ascending Dose Study to Evaluate the Safety, Tolerability, and Pharmacokinetics After Intra-articular Injection of LRX712 Into the Knee of Osteoarthritic Patients
Phase of Trial: Phase I
Latest Information Update: 07 Sep 2018
At a glance
- Drugs LRX-712 (Primary)
- Indications Osteoarthritis
- Focus Adverse reactions; First in man
- Sponsors Novartis Pharmaceuticals
- 28 Aug 2018 Planned End Date changed from 19 Sep 2018 to 27 Mar 2019.
- 28 Aug 2018 Planned primary completion date changed from 19 Sep 2018 to 27 Mar 2019.
- 02 Apr 2018 Planned End Date changed from 28 Sep 2018 to 19 Sep 2018.